Company: IMRX
Filing Date: 2025-03-20
Form Type: 424B5
Source: 0001104659-25-026222
Chunk: 1

Company: Immuneering Corp
Filing Date: 2025-03-20
Form: 424B5
Chunk 1
---
, we have not sold any shares of our Class A
common stock pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of
this Prospectus Supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary
offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12 calendar
month period so long as our public float remains below $75.0 million.

We are filing this Prospectus
Supplement to amend the ATM Prospectus to update the maximum amount of shares that we are eligible to sell under General Instruction I.B.6.
As a result of these limitations, we may currently only offer and sell shares of our Class A common stock having an aggregate offering
price of up to $21,503,435.70 pursuant to this Prospectus Supplement in accordance with the terms of the Agreement. However, in the event
that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to one-third
of our public float, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Agreement. In the event
that our public float increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3.
If our public float increases such that we may sell additional amounts under the Agreement and the registration statement of which this
Prospectus Supplement and the ATM Prospectus are a part, we will file another prospectus supplement prior to making additional sales.

Our Class A common stock
trades on the Nasdaq Global Market under the symbol “IMRX.” On March 20, 2025, the last reported sale price of our Class A
common stock on the Nasdaq Global Market was $1.65 per share.

INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” ON PAGE S-6 OF THE ATM PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR CLASS A COMMON STOCK.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or